Anti-Monomeric C-Reactive Protein Antibody Ameliorates Arthritis and Nephritis in Mice

J Immunol. 2021 Oct 1;207(7):1755-1762. doi: 10.4049/jimmunol.2100349. Epub 2021 Sep 1.

Abstract

Conformation-specific Ags are ideal targets for mAb-based immunotherapy. Here, we demonstrate that the monomeric form of C-reactive protein (mCRP) is a specific therapeutic target for arthritis and nephritis in a murine model. Screening of >1800 anti-mCRP mAb clones identified 3C as a clone recognizing the monomeric, but not polymeric, form of CRP. The anti-mCRP mAb suppressed leukocyte infiltration in thioglycollate-induced peritonitis, attenuated rheumatoid arthritis symptoms in collagen Ab-induced arthritis model mice, and attenuated lupus nephritis symptoms in MRL/Mp-lpr/lpr lupus-prone model mice. These data suggest that the anti-mCRP mAb 3C has therapeutic potential against rheumatoid arthritis and lupus nephritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Experimental / immunology*
  • Arthritis, Rheumatoid / immunology*
  • Arthritis, Rheumatoid / therapy
  • C-Reactive Protein / immunology*
  • Disease Models, Animal
  • Humans
  • Immunotherapy / methods*
  • Lupus Nephritis / immunology*
  • Lupus Nephritis / therapy
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Mice, Inbred MRL lpr
  • Peritonitis / immunology*
  • Peritonitis / therapy
  • Pleura / metabolism*
  • Protein Binding
  • Protein Conformation
  • Protein Isoforms
  • Thoracentesis

Substances

  • Antibodies, Monoclonal
  • Protein Isoforms
  • C-Reactive Protein